SIRPA and lung carcinoma: Taken together, we in this study conclude that lack of SIRPα attenuated lung cancer growth in mice by reducing SHP‐1/STAT3/p38 MAPK signalling, subsequently suppressing IL‐6 expression, meanwhile improving M1 and N1 subtypes and their phagocytosis activity (Figure 7).